Continuous Diaphragm Monitoring of mechanically ventilated patients

Projektinformationen

DiaMon

ID Finanzhilfevereinbarung: 768260

DOI

10.3030/768260

Projekt abgeschlossen

EK-Unterschriftsdatum 11 Juli 2017

Startdatum 1 August 2017

Enddatum 31 März 2020

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten

€ 2 988 500,00

EU-Beitrag

€ 2 988 500,00

Koordiniert durch

RESPINOR AS
Norway

Periodic Reporting for period 2 - DiaMon (Continuous Diaphragm Monitoring of mechanically ventilated patients)

Berichtszeitraum: 2018-11-01 bis 2020-03-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Respinor DXT (Diaphragm Excursion Technology) is a novel, non-invasive, ultrasound-based medical device for continuous monitoring of the diaphragm, the main breathing muscle. It provides real-time, continuous feedback and is operator independent.
It is highly important, both clinically and economically, to bring patients off Mechanical Ventilation (MV) and back to normal, spontaneous breathing as quickly as possible. There is currently a severe lack of accurate, cost-effective solutions to support the MV weaning process. Patients on MV are expensive patients, and our technology will provide significant cost benefits to the hospitals and society at large..
Respinor offers accurate and continuous monitoring of diaphragm movement and respiratory rate over time in a user-friendly and operator-independent manner to assist clinical decision-making regarding liberation from MV.
Respinor DXT provide an objective measure of breathing for critically ill patients on a continuous basis. An easy to use, per patient sensor kit which provides real-time information of diaphragm function and respiratory parameters.
To show clinical usefulness of Respinor DXT is the overall objective of this project.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Respinor has developed a new branding, identified our main challenges and tactical choices for 2018-19 and developed a communication plan. We have created an awareness campaign which we have presented at different meetings to increase awareness about our product offerings and secure that we capitalize on the momentum as the H2020 winner both in phase 1 and phase 2. To ensure successful commercial exploitation we’ve developed an overall exploitation plan. Our pre-launch activities are targeting key customers who initially are defined as: investors, principal investigators, KOLs and potential distribution partners.

On the technical side advances in the project has led to the preparation of new intellectual property the form of two new patent applications.

The company has obtained approval to conduct clinical feasibility studies at four sites in Europe within mechanical ventilation (MV).

Respinor DXT was exhibited for the first time at the ICU Recovery meeting in Leuven in November of 2018. Further Respinor DXT was given exposure both at the Norwegian-Chinese summit in Beijing in October 2018 and at a Norway Health Tech cluster meeting to Minneapolis, USA.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Our technology has a broad range of potential benefits and represents an enabling technology platform for applications in critical care and other areas of respiratory medicine.

The current clinical studies aim to show that Respinor DXT has the potential to predict successful liberation from MV and to reduce the length of stay and potential morbidity associated with MV.

Respinor DXT is estimated to launch in the EU by the end of 2020 and expand into other key markets globally.

Respinor DXT is protected by several patents, patent applications and trademarks.

Image of Respinor DXT

Respinor logo